Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia

被引：0
|
作者：
Mike Dennis
Michelle Davies
Stuart Oliver
Roy D’Souza
Laura Pike
Paul Stockman
机构：
[1] The Christie NHS Foundation Trust,
[2] AstraZeneca,undefined
[3] Alderley Park,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 70卷
关键词：
Barasertib; Acute myeloid leukemia; Pharmacokinetics; Metabolism; Phase I;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：461 / 469
页数：8
相关论文
共 50 条
  • [1] Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
    Dennis, Mike
    Davies, Michelle
    Oliver, Stuart
    D'Souza, Roy
    Pike, Laura
    Stockman, Paul
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (03) : 461 - 469
  • [2] Phase I Study of the Aurora B Kinase Inhibitor Barasertib (AZD1152) to Assess the Pharmacokinetics (PK), Metabolism and Excretion in Patients (pts) with Relapsed or Refractory Acute Myeloid Leukemia (AML)
    Dennis, Mike
    Davies, Michelle
    Oliver, Stuart
    D'Souza, Roy
    Pike, Laura
    Stockman, Paul
    BLOOD, 2011, 118 (21) : 1116 - 1116
  • [3] A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia
    Tsuboi, Kosuke
    Yokozawa, Toshiya
    Sakura, Toru
    Watanabe, Takashi
    Fujisawa, Shin
    Yamauchi, Takahiro
    Uike, Naokuni
    Ando, Kiyoshi
    Kihara, Rika
    Tobinai, Kensei
    Asou, Hiroya
    Hotta, Tomomitsu
    Miyawaki, Shuichi
    LEUKEMIA RESEARCH, 2011, 35 (10) : 1384 - 1389
  • [4] A PHASE I STUDY OF AZD1152, AN AURORA B KINASE INHIBITOR, IN JAPANESE PATIENTS WITH ADVANCED ACUTE MYELOID LEUKEMIA
    Miyawaki, S.
    Ando, K.
    Yokozawa, T.
    Yamauchi, T.
    Watanabe, T.
    Fujisawa, S.
    Uike, N.
    Sakura, T.
    Yagawa, K.
    Hotta, T.
    ANNALS OF ONCOLOGY, 2010, 21 : 176 - 176
  • [5] Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia
    Lowenberg, Bob
    Rousselot, Philippe
    Martinelli, Giovanni
    Goudie, Alison
    Stockman, Paul
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 821 - 821
  • [6] Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
    Schwartz, Gary K.
    Carvajal, Richard D.
    Midgley, Rachel
    Rodig, Scott J.
    Stockman, Paul K.
    Ataman, Ozlem
    Wilson, David
    Das, Shampa
    Shapiro, Geoffrey I.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 370 - 380
  • [7] Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
    Gary K. Schwartz
    Richard D. Carvajal
    Rachel Midgley
    Scott J. Rodig
    Paul K. Stockman
    Ozlem Ataman
    David Wilson
    Shampa Das
    Geoffrey I. Shapiro
    Investigational New Drugs, 2013, 31 : 370 - 380
  • [8] Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia
    Lowenberg, Bob
    Muus, Petra
    Ossenkoppele, Gert
    Rousselot, Philippe
    Cahn, Jean-Yves
    Ifrah, Norbert
    Martinelli, Giovanni
    Amadori, Sergio
    Berman, Ellin
    Sonneveld, Pieter
    Jongen-Lavrencic, Mojca
    Rigaudeau, Sophie
    Stockman, Paul
    Goudie, Alison
    Faderl, Stefan
    Jabbour, Elias
    Kantarjian, Hagop
    BLOOD, 2011, 118 (23) : 6030 - 6036
  • [9] Aurora kinase B inhibitor barasertib (AZD1152) inhibits glucose metabolism in gastric cancer cells
    He, Jian
    Qi, Zihao
    Zhang, Xiaofei
    Yang, Yufei
    Liu, Fei
    Zhao, Guangfa
    Wang, Ziliang
    ANTI-CANCER DRUGS, 2019, 30 (01) : 19 - 26
  • [10] Phase I and pharmacological study of AZD1152, a selective inhibitor of aurora kinase B
    Boss, D. S.
    Witteveen, P. O.
    Mergui, M.
    van der Sar, J.
    Stockman, P. K.
    Voest, E. E.
    Beijnen, J. H.
    Schellens, J. H. M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (05) : 782 - 783
12345